中国组织工程研究

中国组织工程研究 ›› 2012, Vol. 16 ›› Issue (1): 167-170.doi: 10.3969/j.issn.1673-8225.2012.01.036

• 干细胞学术探讨 stem cell academic discussion • 上一篇    下一篇

细胞工程和基因技术修复已损害的房室传导或建立人工房室通路*★

董  皓1，李  萍1，李  璇2   

  1. 1Department of Cardiovascular Medicine, the Second Affiliated Hospital of Nanchang University, Nanchang  330066, Jiangxi Province, China; 2Medical College of Nanchang University, Nanchang  330066, Jiangxi Province, China
  • 收稿日期:2011-06-12 修回日期:2011-07-10 出版日期:2012-01-01 发布日期:2012-01-01
  • 通讯作者: 李萍，博士，教授，主任医师，硕士生导师，南昌大学第二附属医院心血管内科，江西省南昌市 330006 lipingsydney@163.com
  • 作者简介:董皓★，男，1987年生，江西省湖口县人，汉族，南昌大学研究生院医学部在读硕士，主要从事基因细胞工程和生物起搏方面的研究。 tinymice@163.com
  • 基金资助:

    国家自然科学基金资助课题项目(30960125)。

Genetic engineering and cell engineering for repair of damaged atrioventricular conduction or construction of artificial atrioventricular bypass

Dong Hao1, Li Ping1, Li Xuan2   

  1. 1 南昌大学第二附属医院心血管内科，江西省南昌市  330006；2南昌大学医学院，江西省南昌市 330006
  • Received:2011-06-12 Revised:2011-07-10 Online:2012-01-01 Published:2012-01-01
  • Contact: Li Ping, Doctor, Professor, Chief physician, Master’s supervisor, Department of Cardiovascular Medicine, the Second Affiliated Hospital of Nanchang University, Nanchang 330066, Jiangxi Province, China lipingsydney@163.com
  • About author:Dong Hao★, Studying for master’s degree, Department of Cardiovascular Medicine, the Second Affiliated Hospital of Nanchang University, Nanchang 330066, Jiangxi Province, China tinymice@163.com
  • Supported by:

     the National Natural Science Foundation of China, No. 30960125*

PDF

324

摘要：

背景：利用细胞工程和基因技术治疗缓慢性心律失常具有不需要外来能源，不受机体神经激素调控的特点，是更为接近人体的起搏方式，具有药物和电子起搏治疗所无法比拟的优势。
目的：综述目前利用细胞工程和基因技术治疗缓慢性心律失常的进展及存在的问题。
方法：检索2000-01/2011-06 PubMed数据库和万方数据库相关文献。
结果与结论：基因工程技术治疗缓慢性心律失常最早被关注的是β2肾上腺素受体基因、Kir2.1基因，目前研究热门的为HCN基因、AC-VI基因和Tbx3基因。细胞工程中的干细胞移植(包括基因修饰干细胞移植)、细胞融合以及新兴的诱导多能干细胞和成体心肌干细胞移植技术也展示了其治疗缓慢性心律失常的巨大潜能。因此，利用细胞工程和基因技术修复已经损害的房室传导通路或建立一个人工的房室旁路，允许正常的窦性电活动传导至心室是一个更好的选择，但仍很多关键的问题有待解决，比如最佳化的房室延迟、自动应答的程序设计、人工通路的位置如何固定等。
关键词：缓慢性心律失常；细胞工程；基因工程；生物起搏
doi:10.3969/j.issn.1673-8225.2012.01.036

关键词: 缓慢性心律失常, 细胞工程, 基因工程, 生物起搏

Abstract:

BACKGROUND: Using cell-engineering and gene technology to treat bradyarrhythmia has features such as not requiring external energy resource and not being regulated by the neural hormone. It is a way which is more similar to the nature human body. These advantages are incomparable to drugs and electronic pacing.
OBJECTIVE: To review the development and existing problems in using genetic engineering and cell engineering to treat bradyarrhythmia.
METHODS: A computer online search was performed to retrieve papers published between 2000-01 and 2011-06 in PubMed and CNIK database.
RESULTS AND CONCLUSION: Genetic engineering healing bradyarrhythmia paid close attention to β2-adrenergic receptor and Kir2.1 first. And HCN, AC-VI and Tbx3 are the most popular ones in recent research. The stem cell transplantations including the stem cell modified by gene, the combination of cells, iPS and CSCs have displayed their great potential in the treatment of bradyarrhythmia. The obvious alternative here would be to build an atrioventricular bypass tract to permit the normal sinus nodal impulse to propagate to the ventricle. However, there are still a lot of key issues to deal with, such as the optimization of the atrioventricular delay, the program design of automatically responding and the position of the artificial bypass tract.
 

中图分类号: